Effect of direct-acting antiviral drugs on portal circulation hemodynamics in cirrhotic patients infected with HCV
Abstract Background Liver cirrhosis (LC) is the most common cause of portal hypertension. In chronic hepatitis C patients who are treated with direct-acting antiviral therapy (DAAS), the progression of cirrhosis can be reversed with treatment. Portal hypertension is also expected to improve with a v...
Main Authors: | Alshymaa A. Hassnine, Wail Soliman, Amr M. Elsayed, Mahmoud M. Higazi, Mery Saied, Ehab M. Abdelraheem |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2022-02-01
|
Series: | Egyptian Liver Journal |
Subjects: | |
Online Access: | https://doi.org/10.1186/s43066-022-00181-4 |
Similar Items
-
Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study
by: Filomena Morisco, et al.
Published: (2021-07-01) -
HCV cure for everyone or which challenges remain?
by: Jürgen Kurt Rockstroh
Published: (2015-04-01) -
Hypergammaglobulinemia before Starting DAA Therapy Is A Strong Predictor of Disease Progression in Cirrhotic Patients Even after HCV Clearance
by: Maria Stella Franzè, et al.
Published: (2022-10-01) -
Effect of Direct Antiviral Therapy Against HCV on CD4+ T Cell Count in Patients with HIV-HCV Coinfection
by: Pinchera B, et al.
Published: (2023-02-01) -
Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital
by: Nahed Mohammed Hawsawi, et al.
Published: (2023-01-01)